Affiliation: Mount Sinai School of Medicine
- Magnetic resonance imaging of meningoradiculomyelitis in early disseminated Lyme diseaseMark J Tullman
Departments of Neurology and Neuroradiology, Mount Sinai School of Medicine, New York, New York, USA
J Neuroimaging 13:264-8. 2003..The authors present the clinical and radiographic findings, both before and after treatment, in a patient with meningoradiculomyelitis due to early disseminated Lyme disease...
- Clinically isolated syndrome and multiple sclerosis: rethinking the arsenalKrupa Pandey
Fred D Lublin, MD Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street, Box 1138, New York, NY 10029, USA
Curr Treat Options Neurol 11:193-202. 2009..Treatment should also be initiated early in patients with clinically isolated syndrome because they are at high risk for developing clinically definite multiple sclerosis...
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA Electronic address
Lancet 387:1075-84. 2016..We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis...
- Natalizumab reduces relapse clinical severity and improves relapse recovery in MSFred D Lublin
Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for MS, 5 E 98th Street, Box 113B, New York, NY, USA Electronic address
Mult Scler Relat Disord 3:705-11. 2014....
- Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose studyFred D Lublin
Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY 10029, United States Electronic address
Mult Scler Relat Disord 3:696-704. 2014..Infusion of PDA-001, a preparation of mesenchymal-like cells derived from full-term human placenta, is a new approach in the treatment of patients with multiple sclerosis...
- MS as a gateway diseaseFred D Lublin
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY 10029 6574, United States Electronic address
J Neurol Sci 333:73-5. 2013..Doing so will have benefits not only for MS, but potentially for other neurodegenerative diseases. ..
- Atypical Chédiak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative diseaseJames D Weisfeld-Adams
Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA
Orphanet J Rare Dis 8:46. 2013....
- Randomized study combining interferon and glatiramer acetate in multiple sclerosisFred D Lublin
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Ann Neurol 73:327-40. 2013....
- Multiple sclerosis trial designs for the 21st century: building on recent lessonsFred Lublin
Saunders Family Professor of Neurology, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, 5 East 98th Street, 1138, New York, NY 10029 6574, USA
J Neurol 252:v46-53. 2005..In addition to the increased need for enhanced safety assessment, this issue will have an impact both on the study of combination therapies and on the use of combinations in clinical practice...
- History of modern multiple sclerosis therapyFred Lublin
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029 6574, USA
J Neurol 252:iii3-iii9. 2005..There is now a much better understanding of the pathogenesis of the disease, but new and improved therapeutic approaches are still needed...
- Clinical features and diagnosis of multiple sclerosisFred D Lublin
Mount Sinai Medical Center, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street, Box 1138, New York, NY 10029 6574, USA
Neurol Clin 23:1-15, v. 2005
- Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MSF D Lublin
Department of Neurology, Mount Sinai School of Medicine, New York 10029 6574, USA
Ann Neurol 49:677-81. 2001..Patients who decline to utilize available treatments, after proper education and counseling, or those that fail all therapies can be considered to have no treatment alternatives and thus may participate in a placebo-controlled trial...
- Effect of relapses on development of residual deficit in multiple sclerosisFred D Lublin
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
Neurology 61:1528-32. 2003..To determine the percentage of patients with residual deficits following multiple sclerosis (MS) exacerbations and the magnitude of those deficits using a database of pooled placebo patients from clinical trials...
- When marketing and science intersect: do patients with MS benefit?Fred D Lublin
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029 6574, USA
Neurology 59:1480-1. 2002
- The incomplete nature of multiple sclerosis relapse resolutionFred D Lublin
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, 5 East 98th Street, Box 1138, New York, New York 10029, USA
J Neurol Sci 256:S14-8. 2007....
- Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MSAsaff Harel
Department of Neurology, Mount Sinai Hospital, New York, New York, United States of America
PLoS ONE 11:e0152180. 2016..Interestingly, PSIR was more sensitive to new CL accumulation over time compared to DIR. PSIR is a promising technique to monitor cortical damage and disease progression in patients with PPMS over a short-term follow-up. ..
- Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis ConsortiumIlya Kister
Multiple Sclerosis Care Center, Department of Neurology, New York University School of Medicine, NYU Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003 3804, USA
Mult Scler 17:725-33. 2011..Although the natural history of multiple sclerosis has been charted extensively, it is still not known whether the trajectory of disability accumulation has changed in the era of disease-modifying therapies (DMTs)...
- Multiple sclerosis: new treatment trials and emerging therapeutic targetsTracy DeAngelis
Department of Neurology, Mount Sinai School of Medicine New York, New York, USA
Curr Opin Neurol 21:261-71. 2008..This review focuses on new therapeutic strategies in multiple sclerosis...
- The diagnosis of multiple sclerosisFred D Lublin
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY, USA
Curr Opin Neurol 15:253-6. 2002..These new guidelines should provide for the earlier and easier diagnosis of multiple sclerosis, useful for both clinical trials and neurological practice...
- Combination therapy in multiple sclerosisMark J Tullman
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY 10029, USA
Curr Neurol Neurosci Rep 5:245-8. 2005..Rigorously controlled studies are needed to determine the safest and most effective use of new and existing MS therapies...
- Use of interferon-beta in the treatment of multiple sclerosisJoy Derwenskus
Department of Neurology, Northwestern University, Chicago, Illinois, USA
Adv Neurol 98:257-71. 2006
- Immunotherapy of multiple sclerosis--current practice and future directionsMark J Tullman
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
J Rehabil Res Dev 39:273-85. 2002..Although effective, these therapies have a modest impact on reduction in relapse rate and slowing of disease progression. Much work is needed to improve upon this modest effect and hopefully obtain a cure...
- Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple SclerosisSerena Ruggieri
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York2Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
JAMA Neurol 72:1466-74. 2015....
- Novel Agents for Relapsing Forms of Multiple SclerosisRebecca Straus Farber
Icahn School of Medicine at Mount Sinai, New York, NY 10029 email
Annu Rev Med 67:309-21. 2016..We also review available data for promising agents that are currently in late-phase clinical trials, including daclizumab, ocrelizumab, and ofatumumab. ..
- Differentiating multiple sclerosis from other causes of demyelination using diffusion weighted imaging of the corpus callosumRebecca Straus Farber
Mount Sinai Medical Center, Department of Neurology, New York, NY 10029, USA
J Magn Reson Imaging 30:732-6. 2009....
- Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategiesTracy DeAngelis
Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
Mt Sinai J Med 75:157-67. 2008..This review will highlight recent promising therapeutic strategies under investigation in the field of MS...
- Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman
Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
Neurology 71:1134-41. 2008..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Ann Neurol 68:494-502. 2010..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
- Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick
Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Ann Neurol 62:335-46. 2007..To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab...
- Evaluating multiple sclerosisMark J Tullman
J Neurol Sci 218:1-2. 2004
- Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosisA John Petkau
Department of Statistics, University of British Columbia, 333 6356 Agricultural Road, Vancouver, British Columbia, Canada V6T 1Z2
Mult Scler 10:126-38. 2004..In these patients, the influence of NABs may be self-limited, as titers often diminish or NABs become undetectable with time...
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
N Engl J Med 354:911-23. 2006..Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies...
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman
Vrije Universiteit Medical Center, Amsterdam, The Netherlands
N Engl J Med 354:899-910. 2006..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
- Responsiveness and predictive values in PPMS: an uncertain messageGary R Cutter
Neurology 70:1061-2. 2008
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"Chris H Polman
VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Ann Neurol 58:840-6. 2005..The 2005 Revisions to the McDonald Diagnostic Criteria for MS should simplify and speed diagnosis, whereas maintaining adequate sensitivity and specificity...
- Quantitative functional MR imaging of the visual cortex at 1.5 T as a function of luminance contrast in healthy volunteers and patients with multiple sclerosisScott H Faro
Department of Radiological Sciences, MCP Hahnemann University, 3300 Henry Ave, Philadelphia, PA 19129, USA
AJNR Am J Neuroradiol 23:59-65. 2002..We therefore investigated whether varying luminance contrast levels can help uncover subtle changes in fMR imaging characteristics of the visual cortex in healthy volunteers and patients with MS...